<DOC>
	<DOCNO>NCT01433562</DOCNO>
	<brief_summary>This 2-arm , randomize , double-blind , placebo-controlled study aim determine efficacy safety DLBS1425 combination anthracyclin-based regimen neoadjuvant therapy subject previously untreated stage II III ( operable ) breast cancer . The anthracyclin-based regimen study either CAF/iv CEF/iv . The neoadjuvant anthracyclin-based chemotherapy give 3 cycle . The length cycle 21-28 day .</brief_summary>
	<brief_title>Efficacy Safety DLBS1425 Neoadjuvant Stage II III Breast Cancer Patients</brief_title>
	<detailed_description>The duration treatment subject 63 - 84 day ( 3 cycle ) . The cycle initiate Day-1 ( D1 1st cycle ) . The subsequent cycle start Day-22 ( D1 2nd cycle ) Day-43 ( D1 3rd cycle ) . DLBS1425 capsule administer orally every day ( start D1 cycle ) study period . All subject direct supervision medical doctor study period . Clinical laboratory examination evaluate investigational drug 's efficacy safety perform baseline end every cycle study course ; whilst breast-CT scan perform baseline end study course . In addition , end study , discretion Investigator subject ' willingness , subject good response treatment ( i.e . RECIST pathological evaluation regard complete partial response ) may continue breast-cancer therapy DLBS1425 .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Confirmed stage II III ( operable ) primary breast cancer Having radiologically evaluable measurable lesion ( ) primary tumor Karnofsky performance status 80 % Normal cardiac function : LVEF &gt; 50 % Adequate hematological function : Hb ≥ 10.0 g/dL , WBC ≥ 3,000/mm3 , ANC ≥ 1,500 /mm3 , platelet count ≥ 100,000/mm3 Adequate liver function : ALT ≤ 2.5 time upper limit normal , total bilirubin level ≤ 1.5 time upper limit normal Adequate renal function : serum creatinine ≤ 1.5 time upper limit normal Able take oral medication Pregnancy breast feeding subject History previous breast cancer ( recurrent breast cancer ) History cancer within past 5 year Prior systemic treatment current breast cancer Prior preoperative topical treatment current breast cancer Uncontrolled serious CVD Known suspect hypersensitivity chemotherapeutic agent use study Any serious disease state medical condition judge investigator could interfere trial participation trial evaluation Concurrent herbal ( alternative ) medicine food supplement suspect effect breast cancer disease within 14 day prior screen Severe psychological neurological disorder dementia would preclude understand informed consent Participation clinical study within 30 day prior screen</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>neoadjuvant therapy</keyword>
	<keyword>Stage II/III</keyword>
</DOC>